Anti-PDL1 in seconda linea nel NSCLC: il ruolo di atezolizumab

Approfondimenti generali

Neoplasie del polmone, Linee Guida AIOM, 2015.

Novello S, et al. Metastatic Non-Small-Cell Lung Cancer: ESMO Clinical Practice Guidelines. Ann Oncol; 2016; 27 (suppl 5): v1-v27

Eberhardt WEE et al. 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancerAnnals of Oncology 26: 1573–1588, 2015

ClinicalTrial.gov. A service of the U.S. National Institutes of Health

Referenze bibliografiche specifiche

Fehrenbacher L. et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. The Lancet 2016; 10030:1837–1846

Smith David A. et al. Updated survival and biomarker analyses of a randomized phase II study of atezolizumab vs docetaxel in 2L/3L NSCLC (POPLAR). 2016 ASCO Annual Meeting, J Clin Oncol 34, 2016 (suppl; abstr 9028)

KIm J.M., Chen D.S. Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). Ann Oncol 2016; 27:1492-1504

Gadgeel S. et al. OAK, a Randomized Ph III Study of Atezolizumab vs Docetaxel in Patients with Advanced NSCLC: Results from Subgroup Analyses Journal of Thoracic Oncology 2017; 12:1S

Herbst Roy S. et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014; 515:563–567

Chen et al. Oncology Meets Immunology:TheCancer-Immunity Cycle. Immunity 2013; 39

© 2016 - 2019 Accademia Nazionale di Medicina - Tutti i diritti riservati